Review published data that define nr-axSpA within the axSpA disease continuum to facilitate more timely diagnoses
|
|
|
|
|
|
Incorporate recently approved or emerging biologic and small-molecule treatments for appropriately selected patients with nr-axSpA, based on efficacy and safety data from clinical trials
|
|
|
|
|
|